The Defense Health Agency awarded the University of Oklahoma Health Sciences Center $557,612 on November 1, 2026, through the Military Medical Research and Development program (CFDA 12.420) to develop a transformative preclinical model for advancing precision immunotherapy in mismatch repair-deficient endometrial cancer. Performance occurs at Oklahoma City, Oklahoma, with work concluding October 31, 2028.